Science Corporation, founded by former Neuralink president Max Hodak, announced it has raised $400 million in a Series D funding round. This investment values the medical technology startup at $3.5 billion. Key investors in this round include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.
The company's initial product, PRIMA, is a wearable and implantable chip designed to help individuals with age-related macular degeneration recover vision. PRIMA is currently approved in Europe and available in Germany. Science Corporation is also trialing PRIMA for Stargardt disease, another cause of blindness. The new funding will facilitate the device's entry into the United States via the FDA’s Humanitarian Device Exemption, which allows experimental medical technology for rare conditions.
Beyond PRIMA, Science Corporation's long-term goal is to establish direct connections with the human brain using a bio-hybrid sensor. This sensor combines cultured neurons with silicon components. The company is currently designing initial human trials for this device in collaboration with Yale neurosurgery professor Murat Günel, with potential applications for conditions like Parkinson’s disease and other brain injuries.
The substantial funding and valuation underscore investor confidence in Science Corporation's approach to neurotechnology. The expansion of PRIMA into the U.S. market could offer new treatment options for specific vision impairments, while the development of its bio-hybrid brain sensor represents a step toward advanced treatments for neurological disorders.
✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →
One email each morning: the day's tech stories, clustered across outlets and summarized. No account needed.
One email a day. Unsubscribe in one click, any time.
Spend a few minutes, get the whole day. Every topic's top stories in one hands-free rundown — listen, watch, or read the transcript.
▶ Play today's briefNew every morning, and the back catalogue is archived by date.
Science Corporation, a medical technology startup, secured $400 million in Series D funding, bringing its valuation to $3.5 billion. This funding will support the company's efforts to bring its PRIMA vision-restoration device to the U.S. market and advance its bio-hybrid brain sensor technology.